Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Event-driven biotech momentum: shares are up about 42% over 21 trading days, Corcept raised 2026 revenue guidance, plans to resubmit the relacorilant NDA in Cushing's syndrome, and recent clinical updates keep the catalyst calendar active.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Higher-high trend ⢠Strong support hold ⢠Extended rally risk Support Level: $89-$91 Resistance Level: $96.66-$100 CORT is in a strong uptrend with firm $89-$91 support, but the sharp move leaves it extended near $96.66 resistance and at risk of consolidation or a brief pullback.
Sentiment & News
Key News Insights: ⢠Earnings catalyst ⢠Legal scrutiny ⢠Insider selling Corcept shows solid commercial and pipeline momentum, but the relacorilant setback, fiduciary-duty review, and insider selling keep sentiment cautious ahead of its July 29 earnings update.
AI Summary
CORT has shifted from a binary single-product biotech to a cash-generating commercial platform with Korlym plus a potentially much larger relacorilant growth engine, but at this valuation the stock now looks more like a âprove-and-deliverâ story where FDA execution, launch uptake, and any slip in growth could hit hard because much of the upside appears already priced in.
Description
Corcept Therapeutics is a U.S.-based biopharmaceutical company that discovers, develops and commercializes drugs for severe metabolic, oncologic and neuropsychiatric conditions. It markets Korlym (mifepristone) for hyperglycemia secondary to endogenous Cushingâs syndrome in adults with type 2 diabetes or glucose intolerance who have not had successful surgery or are ineligible, and has clinical-stage programs including relacorilant for Cushingâs and combination studies with nab-paclitaxel in advanced ovarian tumors, alongside separate programs targeting prostate cancer, antipsychotic-induced weight gain and FKBP5-related diagnostics. Founded in 1998, the company is headquartered in Menlo Park, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 8 | Jun 15 | CORT | Corcept Therapeutics Incorporated | Event-driven biotech momentum: shares are up about 42% over 21 trading days, Corcept raised 2026 revenue guidance, plans to resubmit the relacorilant NDA in Cushing's syndrome, and recent clinical updates keep the catalyst calendar active. | Closed | +13.4% |